Does Presbyterian Healthcare Services Cover Prolia?

How Presbyterian Healthcare Services Classifies Prolia

Presbyterian Healthcare Services, the largest health system and managed care organization in New Mexico, classifies Prolia (denosumab 60 mg) as a specialty biologic medication on its pharmacy formulary. Because Prolia is administered by subcutaneous injection in a healthcare setting every six months, it often falls under the medical benefit rather than the pharmacy benefit. This distinction matters for how your cost-sharing is calculated.

On most Presbyterian commercial plans, Prolia sits on a specialty or non-preferred brand tier. The FDA approved denosumab in 2010 for postmenopausal women at high risk of fracture, and the drug has since gained additional indications for glucocorticoid-induced osteoporosis, bone loss in men receiving androgen deprivation therapy for prostate cancer, and bone loss in women receiving aromatase inhibitor therapy for breast cancer. Presbyterian's formulary decisions align with these FDA-labeled uses.

Coverage also extends to Presbyterian's Centennial Care program, which serves New Mexico Medicaid recipients. Under Centennial Care, Prolia requires prior authorization but carries minimal or zero cost-sharing for eligible members. Presbyterian Medicare Advantage plans cover Prolia under Medicare Part B guidelines, where it is classified as a physician-administered injectable [1].

Prior Authorization Requirements

Before Presbyterian will approve Prolia coverage, your prescribing physician must submit a prior authorization request. This is standard practice across nearly all commercial and government-sponsored Presbyterian plans, not unique to this insurer.

The prior authorization process typically requires documentation of the following: a confirmed diagnosis of osteoporosis based on a DXA scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip; a history of fragility fracture; or a 10-year fracture probability calculated using the FRAX tool that meets intervention thresholds. The National Osteoporosis Foundation (now the Bone Health & Osteoporosis Foundation) recommends pharmacologic treatment when the FRAX 10-year probability of hip fracture reaches 3% or major osteoporotic fracture reaches 20%.

Presbyterian typically requires evidence that the patient has tried and failed, or has a documented contraindication to, at least one oral bisphosphonate such as alendronate or risedronate. Contraindications that satisfy this step therapy requirement include esophageal disorders (Barrett's esophagus, esophageal stricture), inability to remain upright for 30 minutes, documented gastrointestinal intolerance, or renal impairment with an estimated GFR below 30-35 mL/min. The Endocrine Society's 2020 guidelines support denosumab as a first-line option when bisphosphonates are contraindicated or poorly tolerated [2].

Authorization decisions are usually returned within 48 to 72 hours for standard requests. Urgent requests can be processed within 24 hours.

Step Therapy and Formulary Placement

Presbyterian employs step therapy protocols for Prolia that mirror industry-wide patterns. Generic alendronate costs insurers roughly $10 to $30 per month, while Prolia's wholesale acquisition cost exceeds $1,800 per injection. This price differential drives the requirement to try less expensive alternatives first.

The typical step therapy sequence on a Presbyterian plan follows this pattern. Patients start with an oral bisphosphonate, usually generic alendronate 70 mg weekly or risedronate 35 mg weekly. If the patient demonstrates treatment failure (defined as a new fracture on therapy, continued significant bone density decline on follow-up DXA, or documented poor absorption), intolerance, or has a medical contraindication, the plan then authorizes Prolia.

In the FREEDOM trial (N=7,868), denosumab 60 mg every six months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared to placebo over 36 months [3]. These results established Prolia as one of the most effective antiresorptive therapies available, and they form the clinical foundation for coverage approval when step therapy criteria are met.

Patients with glucocorticoid-induced osteoporosis may bypass step therapy entirely on some Presbyterian plans. The American College of Rheumatology's 2022 guideline for glucocorticoid-induced osteoporosis conditionally recommends denosumab as an appropriate initial therapy for adults age 40 and older taking prednisone 2.5 mg or more daily for three months or longer who are at moderate-to-high fracture risk [4].

What You Will Pay Out of Pocket

Your actual cost for Prolia under a Presbyterian plan depends on several variables: your specific plan design, whether you have met your annual deductible, whether Prolia is billed under your medical or pharmacy benefit, and your plan's specialty drug cost-sharing structure.

For Presbyterian commercial plans, specialty tier copays typically range from $50 to $300 per injection after the deductible is met. Some plans use coinsurance instead, requiring the patient to pay 20% to 30% of the allowed amount. Since Prolia's list price is approximately $1,826 per injection (per the 2024 Amgen pricing data), a 20% coinsurance could mean over $350 per dose before any copay assistance is applied. Annual out-of-pocket maximums cap total spending, and two Prolia injections per year mean these caps are reached quickly for patients on multiple specialty medications [5].

Presbyterian Centennial Care (Medicaid) members generally pay $0 to minimal copays for Prolia once prior authorization is approved. New Mexico Medicaid fee schedules cover physician-administered Part B drugs at rates tied to the Average Sales Price plus a percentage markup.

Presbyterian Medicare Advantage enrollees receive Prolia under Medicare Part B. The standard Part B cost-sharing is 20% of the Medicare-approved amount after the Part B deductible ($240 in 2024). Patients with Medigap supplemental coverage may have this 20% covered entirely.

How to Get Prolia Covered If You Are Initially Denied

Denials happen. They are not the end of the road. Presbyterian, like all managed care organizations, has a formal appeals process governed by New Mexico Insurance Division regulations and federal parity requirements.

The most common reasons for initial denial include incomplete clinical documentation, failure to demonstrate bisphosphonate trial or contraindication, an expired or missing DXA scan, or a diagnosis code that does not match the approved indications. Each of these is fixable.

For a successful appeal, your physician should submit a letter of medical necessity that includes the specific diagnosis with ICD-10 code (M81.0 for age-related osteoporosis without fracture, M80.0 for age-related osteoporosis with fracture), the most recent DXA results with T-scores, FRAX calculation if applicable, documentation of prior bisphosphonate use or contraindication, and relevant guideline citations supporting denosumab for the patient's clinical scenario.

The AACE/ACE 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis classify denosumab as appropriate initial therapy for patients at very high fracture risk, defined as a recent fracture within 12 months, fractures while on approved osteoporosis therapy, multiple fractures, T-score below -3.0, or high fall risk [6]. Citing this guideline in an appeal strengthens the case for coverage without prior bisphosphonate use.

Presbyterian must respond to standard appeals within 30 calendar days. Expedited appeals for urgent clinical situations require a response within 72 hours. If the internal appeal is denied, New Mexico residents can request an external independent review through the New Mexico Office of Superintendent of Insurance.

Amgen's Copay Assistance and Alternative Financial Support

Amgen, the manufacturer of Prolia, offers a copay card program for commercially insured patients that can reduce out-of-pocket costs to as little as $0 per injection. This program is available to patients with private insurance, including Presbyterian commercial plans. It is not available to patients enrolled in Medicare, Medicaid, TRICARE, or other government-funded programs.

For Medicare patients on Presbyterian Medicare Advantage plans, alternative assistance options include the Amgen Safety Net Foundation, which provides Prolia at no cost to patients who meet income eligibility criteria (generally household income at or below 400% of the federal poverty level). The Medicare Part B Senior Savings Model, where available, can also cap insulin and certain Part B drug costs, though Prolia is not always included.

Patients should also check whether their Presbyterian plan participates in any specialty pharmacy programs that negotiate lower net costs for Prolia. Presbyterian's preferred specialty pharmacy network may offer lower copays than out-of-network specialty pharmacies [7].

Clinical Considerations That Affect Coverage Decisions

Several clinical scenarios influence how Presbyterian evaluates Prolia coverage requests. Understanding these can help patients and physicians anticipate and address potential barriers.

Renal impairment is one area where Prolia has a distinct advantage. Bisphosphonates are contraindicated or require dose adjustments when the estimated GFR falls below 30-35 mL/min. Denosumab, because it is a monoclonal antibody cleared by the reticuloendothelial system rather than renally excreted, does not require renal dose adjustment [8]. For patients with chronic kidney disease stages 4-5, physicians can request Prolia as first-line therapy without prior bisphosphonate trial, and Presbyterian plans typically approve these requests.

Discontinuation risk is another factor. The FDA issued a drug safety communication warning that stopping Prolia can cause a rapid rebound in bone turnover and an increased risk of multiple vertebral fractures, particularly within 7 to 12 months of the last dose [9]. Presbyterian may require documentation that the prescriber has a transition plan (typically to a bisphosphonate) before authorizing Prolia, and this requirement protects patients from the clinical consequences of unplanned discontinuation.

The 10-year extension data from the FREEDOM trial showed that continuous denosumab use for up to 10 years maintained fracture risk reduction with no plateau in bone density gains. Lumbar spine BMD increased by 21.7% and total hip BMD by 9.2% over 10 years of continuous therapy [10]. This long-term efficacy data supports ongoing coverage authorization for patients who respond to treatment.

Hypocalcemia monitoring is required before each Prolia injection. Serum calcium and 25-hydroxyvitamin D levels should be checked, and any deficiency corrected before administration. Presbyterian may include this as a condition of continued authorization. The Endocrine Society recommends maintaining serum 25(OH)D levels at 30 ng/mL or above in patients on antiresorptive therapy [11].

Presbyterian Centennial Care and Prolia for Medicaid Recipients

New Mexico's Centennial Care program, administered by Presbyterian and other managed care organizations, covers Prolia for Medicaid-eligible residents who meet clinical criteria. The program serves over 900,000 New Mexicans, and osteoporosis disproportionately affects the state's aging and underserved populations.

Under Centennial Care, prior authorization follows the same clinical pathway as commercial plans. The key difference is cost: Medicaid recipients face no or nominal copays for approved specialty medications. The New Mexico Human Services Department's Preferred Drug List includes coverage pathways for denosumab when bisphosphonates are inappropriate.

For Centennial Care members denied Prolia coverage, the managed care grievance and appeal process is supplemented by the right to request a fair hearing through the New Mexico Human Services Department. This provides an additional layer of consumer protection beyond the standard internal appeal.

Physicians serving Centennial Care patients should use the Presbyterian provider portal to submit prior authorization requests electronically. Typical turnaround is two to three business days. Phone-based urgent requests are processed within 24 hours.

Comparing Prolia to Other Covered Osteoporosis Treatments on Presbyterian Plans

Presbyterian's formulary includes several osteoporosis medications at different tier levels. Understanding where Prolia fits relative to alternatives helps patients and prescribers make informed decisions.

Generic alendronate and risedronate sit on the lowest (preferred generic) tier with copays typically under $15. Ibandronate (monthly oral or quarterly IV) occupies a similar tier position. Zoledronic acid (Reclast), given as a once-yearly IV infusion, is generally covered on a specialty tier but may have lower cost-sharing than Prolia on some Presbyterian plans because of its lower acquisition cost [12].

Teriparatide (Forteo) and abaloparatide (Tymlos), both anabolic agents, sit on the highest specialty tier and require even more extensive prior authorization than Prolia. Romosozumab (Evenity) faces the strictest coverage criteria, often limited to patients with very high fracture risk and cardiovascular risk screening.

Prolia occupies a middle position: more expensive than oral bisphosphonates and zoledronic acid, but less expensive and less restrictively covered than anabolic agents. For patients who need injectable therapy but do not meet criteria for anabolic treatment, Prolia represents the most accessible option on Presbyterian formularies.

The NOF/BHOF guidelines support a treat-to-target approach where therapy is escalated based on fracture risk reassessment, and Prolia fits well as a second-line escalation from oral bisphosphonates [13].